L / RAIN
SHANGHI/SINGAPORE – China inoculates tens of thousands of its citizens with experimental coronavirus vaccines and is generating foreign interest in its development, despite expert considerations on protecting drugs that have not completed popular testing.
China introduced an emergency vaccine use program in July, providing 3 experimental injections developed through a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and Sinovac Biotech, which is listed in the United States. use through the Chinese army in June.
In order to protect essential staff and reduce the likelihood of a resurgence, vaccines are also drawing attention to the global rush of governments for safe supplies, which could help rethink China’s perceived role in the pandemic.
Beijing has published official information on adoption through national target groups, which are staffed in the medical, maritime and food markets.
But China’s National Biotec Group (CNBG), The Sinopharm unit that presents two of the emergency vaccines, and Sinovac showed that at least tens of thousands more people have been vaccinated. In addition, CNBG reported having administered thousands of doses; one of your vaccines requires an individual to get two or three injections to be inoculated.
Beijing has adopted a top-down public technique to pass experimental vaccines and foster network support. Among those queuing for the first shootings were sinovac and Sinopharm general managers and the army’s chief of inquiry.
China’s leading biosecurity expert at China’s Center for Disease Control and Prevention (CDC) revealed this week that it was also injected in April, when he announced the possibility that at least some of the vaccines would be in public use starting in November.
“So far, among the other people who have been vaccinated, no one has been diagnosed with the disease,” Guizhen Wu told state television. “So far, (the vaccination program) is working very well. No side effects occurred. “
Wu’s comments were broadly consistent with CNBG’s comments last week that none of the tens of thousands of others who visited high-risk countries and regions after being vaccinated had become inflamed and that “there were no obvious cases of adverse reaction. “
China’s technique goes against that of many Western countries, where experts have warned that they oppose allowing vaccines that have not completed testing as an emergency, leading to a lack of long-term efficacy and prospective side effects.
Anna Durbin, a vaccine researcher at Johns Hopkins University, described China’s emergency use program as “very problematic,” and said a trial of efficacy was highly unlikely without a popular clinical trial group.
“Vaccines to other people and you don’t know if that will protect them,” Durbin said, adding that experimental vaccine recipients may simply be other protective measures.
Vaccine protection ended last week when AstraZeneca PLC discontinued complex clinical trials of its COVID-19 vaccine, one of the most complex in development.
The company resumed British trials this weekend after receiving green approval from protective watchdogs and, along with other leading Western vaccine manufacturers, pledged to meet clinical criteria and reject any political tensions to speed up the process.
Russia is one of the few other countries that allows the use of an experimental vaccine, which makes its own “Sputnik V” vaccine mandatory for certain groups, adding teachers. India is an emergency authorization for a vaccine, i. e. for the elderly and others in high-risk workplaces.
The United Arab Emirates legalized the emergency use of a Sinopharm vaccine this week, the first foreign emergency authorization for one of China’s vaccines, just six weeks after the start of human trials in arab Gulf state. , but no serious side effects, those trials.
CanSino approached through several countries, said a source close to the talks, adding that the army’s approval had helped attract foreign interest. The user refused to call the countries involved in the conversations.
CanSino, who is making test plans in Pakistan and Russia for the vaccine developed with the Chinese army study unit, responded to a request for comment.
Zhang Yuntao, vice president of CNBG, said his company had attracted interest from foreign countries to buy about 500 million doses of its experimental vaccine.
“China obviously needs to reorient this speech to be seen as a solution that as a cause of the pandemic,” said Yanzhong Huang, a leading global health member of the Foreign Affairs Council, a U. S. -based expert group.
“This story, ironically, may be more convincing when Trump’s ‘America First’ technique denies many countries access to U. S. -made vaccines. “
Philippine President Rodrigo Duterte promised Monday to prioritize China and Russia in their country’s global vaccine purchases, and said his government had already held talks with both. He said China and other countries are looking for “booking fees” or advance payments.
“The only smart thing about China is that you don’t have to beg, you don’t have to beg,” Duterte said. “There is one thing in Western countries: it is all profit, profit, benefit. “
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic. today so that we can continue to provide you with up-to-date and detailed data on Japan.
The Japan Times LTD. All rights are reserved.